NIRAPARIB
niraparib 100 mg tablet, 84
NIRAPARIB (14212B)
14212B
Manner of administration:Oral
Restriction
Indication: High grade stage III/IV epithelial ovarian, fallopian tube or primary peritoneal cancer
Treatment phase: Initial first-line maintenance therapy (genomic instability without BRCA1/2 gene mutation)
in a patient requiring a daily dose of 3 tablets
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 84 | # of repeats: 2 | DPMQ: $9,875.19 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Zejula | |||||